Eric Dobmeier Chinook Therapeutics, Inc. (KDNY) insider trading activity

Eric Dobmeier is President, CEO of CHINOOK THERAPEUTICS, INC.. Currently has a direct ownership of 0 shares of KDNY, which is worth approximately $0. The most recent transaction as insider was on Aug 11, 2023, when has been sold 301,138 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 0

0% 3M change

100.0% 12M change

Total Value Held $0

ERIC DOBMEIER Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Aug 11 2023	SELL Sale (or disposition) back to the issuer	-	301,138 Reduced 100.0%	0 Common Stock
Apr 24 2023	SELL Open market or private sale	$513,603 $21.58 p/Share	23,800 Reduced 7.3%	302,338 Common Stock
Apr 24 2023	BUY Open market or private sale	$26,712 $22.26 p/Share	1,200 Added 0.4%	301,138 Common Stock
Apr 24 2023	BUY Exercise of conversion of derivative security	$10,500 $0.42 p/Share	25,000 Added 7.12%	326,138 Common Stock
Feb 10 2023	SELL Open market or private sale	$192,303 $23.75 p/Share	8,097 Reduced 2.62%	301,138 Common Stock
Feb 10 2023	BUY Exercise of conversion of derivative security	-	20,248 Added 6.15%	309,235 Common Stock
Jan 31 2023	SELL Open market or private sale	$189,739 $24.68 p/Share	7,688 Reduced 2.59%	288,987 Common Stock

Jan 31 2023	BUY Exercise of conversion of derivative security	-	24,999 Added 7.77%	296,675 Common Stock
Jan 30 2023	SELL Open market or private sale	$613,500 $24.54 p/Share	25,000 Reduced 8.43%	271,676 Common Stock
Jan 30 2023	BUY Exercise of conversion of derivative security	$10,500 $0.42 p/Share	25,000 Added 7.77%	296,676 Common Stock
Dec 14 2022	BUY Exercise of conversion of derivative security	$10,500 $0.35 p/Share	30,000 Added 9.94%	271,676 Common Stock
Dec 01 2022	SELL Open market or private sale	$669,300 $22.31 p/Share	30,000 Reduced 11.04%	241,676 Common Stock
Dec 01 2022	SELL Bona fide gift	-	25,000 Reduced 10.56%	211,676 Common Stock
Dec 01 2022	BUY Exercise of conversion of derivative security	$25,200 $0.42 p/Share	60,000 Added 18.09%	271,676 Common Stock
Oct 06 2022	BUY Exercise of conversion of derivative security	-	30,796 Added 11.51%	236,676 Common Stock
May 25 2022	BUY Open market or private purchase	$65,150 $13.03 p/Share	5,000 Added 2.37%	205,880 Common Stock
Feb 10 2022	BUY Exercise of conversion of derivative security	-	20,247 Added 9.16%	200,880 Common Stock
Dec 23 2021	BUY Exercise of conversion of derivative security	$14,000 $0.35 p/Share	40,000 Added 18.13%	180,633 Common Stock
Oct 06 2021	BUY Exercise of conversion of derivative security	-	30,796 Added 17.96%	140,633 Common Stock
Sep 20 2021	BUY Open market or private purchase	$24,000 $12.0 p/Share	2,000 Added 1.79%	109,837 Common Stock
Aug 19 2021	BUY Open market or private purchase	$36,000 $12.0 p/Share	3,000 Added 2.71%	107,837 Common Stock
Aug 18 2021	BUY Open market or private purchase	$82,180 $11.74 p/Share	7,000 Added 6.26%	104,837 Common Stock
Jun 14 2021	BUY Exercise of conversion of derivative security	$7,000 $0.35 p/Share	20,000 Added 16.97%	97,837 Common Stock
May 14 2021	BUY Open market or private purchase	$14,440 $14.44 p/Share	1,000 Added 1.27%	77,837 Common Stock
Dec 21 2020	BUY Exercise of conversion of derivative security	$7,000 $0.35 p/Share	20,000 Added 20.65%	76,837 Common Stock

Also insider at

ADPT

Adaptive Biotechnologies Corp Healthcare

Director

ATRA

Atara Biotherapeutics, Inc. Healthcare

GPCR

Structure Therapeutics Inc.

Eric Dobmeier

President, CEO

Seattle, WA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KDNY shares.

Notify only if

Value

Insider Trading

Get notified when an Chinook Therapeutics, Inc. insider buys or sells KDNY shares.

Notify only if

Operation

Value

Type

News

Receive news related to CHINOOK THERAPEUTICS, INC.

Track Activities on KDNY

Account